| Literature DB >> 27313953 |
Juan E Corral1, Corey W Dye1, Maria R Mascarenhas2, Jamie S Barkin3, Matthias Salathe4, Baharak Moshiree3.
Abstract
Cystic fibrosis (CF) is associated with different gastrointestinal motility disturbances and syndromes. We aim to assess gastric emptying in patients with CF compared to healthy controls by a systematic review of existing literature. Medical databases and abstracts from major gastroenterology and CF meetings were reviewed. Emptying times in CF patients were compared with healthy controls using random effects models. Subgroup analysis stratified results by age and diagnostic modality. Nineteen studies from 7 countries included 574 subjects (359 CF patients and 215 controls). Using pooled analysis frequency of gastroparesis was high (38%, 95% CI 30-45%) but results were highly dependent on the diagnostic modality. Delayed gastric emptying is more common in CF compared to general population. Scintigraphy identified rapid gastric emptying in a subgroup of CF patients, but this finding disappeared with adequate pancreatic enzyme replacement and after other diagnostic modalities were included.Entities:
Year: 2016 PMID: 27313953 PMCID: PMC4904114 DOI: 10.1155/2016/2918139
Source DB: PubMed Journal: Scientifica (Cairo) ISSN: 2090-908X
Figure 1Selection of studies for inclusion in systematic review. DDW: Digestive Disease Week, ACG: American College of Gastroenterology, EUG: United European Gastroenterology, NACFC: North American Cystic Fibrosis Conference, and ECFS: European Cystic Fibrosis Society.
Studies evaluating gastric emptying in cystic fibrosis.
| Author | Year | Location | Subjects | Gender | Age | DM | Pancreatic insufficiency | Intervention | Result | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | Mean | ||||||||||||||
| CF | Controls | Total | CF | Controls | CF | Controls | CF | Controls | CF | Controls | |||||
| Capsule methods | |||||||||||||||
| Hedsund et al. [ | 2012 | Denmark | 10 | 16 |
| 5 | 9 | 23 | 26 | 0 | 0 | 10 | 0 | No | No difference |
| Gelfond et al. [ | 2013 | Buffalo, NY | 10 | 10 |
| 3 | 3 | 21.7 | 22.5 | 0 | 0 | 10 | 0 | No | No difference |
|
| |||||||||||||||
| C-Octanoic breath test | |||||||||||||||
| De Boeck et al. [ | 1998 | Belgium | 11 | — |
| 4 | — | 10.5 | — | — | — | 11 | — | Creon and high-lipase Creon in CF. | No control group |
| Symonds et al. [ | 2003 | Australia | 10 | 12 |
| 5 | 7 | 10.2 | 12.5 | NA | 0 | 10 | 0 | Pancreas in CF | No difference |
| Neumann et al. [ | 2003 | Czech Republic | 20 | — |
| NA | — | 13.5 | — | — | — | — | — | No | No difference |
| Hauser et al. [ | 2010 | Belgium | 19 | — |
| 13 | — | 5 | — | — | — | — | — | No | No control group |
| Pauwels et al. [ | 2011 | Belgium | 33 | — |
| 18 | — | 28 | — | 0 | — | 31 | — | No | No control group |
| Hauser et al. [ | 2013 | Belgium | 22 | — |
| 12 | — | 9 | — | — | — | 0 | — | No | No control group |
|
| |||||||||||||||
| Scintigraphy with technetium | |||||||||||||||
| Davidson et al. [ | 1995 | Canada | 70 | — |
| NA | — | NA | — | — | — | — | — | No | No control group |
| Carney et al. [ | 1995 | Australia | 5 | 11 |
| 3 | 4 | 25 | 21 | 0 | 0 | 5 | 0 | No | CF Faster |
| Collins et al. [ | 1997 | Australia | 19 | 17 |
| 8 | 8 | 12.6 | 12.8 | 2 | 0 | 19 | 0 | Usual dose of PERT in CF | CF Faster |
| Munck et al. [ | 1997 | France | 7 | — |
| NA | — | NA | — | — | — | — | — | Erythromycin in CF | No control group |
| Couturier et al. [ | 2004 | France | 48 | 53 |
| NA | 42 | NA | 31.84 | NA | 0 | NA | 0 | No | CF Slower |
| King et al. [ | 2006 | Australia | 22 | — |
| 8 | — | NA | — | — | — | 18 | — | Usual dose of PERT in CF | No control group |
| Tonelli et al. [ | 2009 | Gainesville, FL | 5 | — |
| 1 | — | 25.2 | — | 2 | — | 5 | — | IV Erythromycin in CF | No control group |
| Luu et al. [ | 2011 | Canada | 17 | — |
| NA | — | NA | — | — | — | — | — | Measurements before and after Cisapride in CF | No control group |
| Kuo et al. [ | 2011 | Australia | 5 | 6 |
| 3 | 3 | 25.8 | 21.7 | 0 | 0 | 5 | 6 | Creon versus Placebo in CF | CF Faster |
| Mendez et al. [ | 2012 | Chicago, Il | 10 | 78 |
| 8 | 38 | 28 | 59 | NA | NA | NA | NA | No | CF Slower |
| Rovner et al. [ | 2013 | Philadelphia, PA | 16 | 12 |
| 9 | 6 | 16.7 | 28.6 | 0 | 0 | 16 | 0 | Creon in CF | No difference |
| 359 | 215 |
| 100 (50.76%)a | 120 (55.81%)a | 4 (5.71%)a | 0 (0.00%)a | 140 (84.85%)a | 6 (4.38%)a | |||||||
aOf available data.
CF: cystic fibrosis and NA: data not available.
Figure 2Forest plot graph for frequency of gastroparesis in cystic fibrosis, divided by measuring technique.
Case-control (higher-quality) studies evaluating gastric emptying in cystic fibrosis.
| Author | Sample | Cystic fibrosis | Controls matching | Food used to deliver marker | PERT before testing | Follow-up time | NOS | Conclusion | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnosis | DM | Mean BMI | Pancreatic insufficiency | Pulmonary function | Medications | |||||||||
| Capsule methods | ||||||||||||||
| Hedsund et al. [ | 26 (10/16) | All had severe classes I–III mutations (7 were ΔF508 homozygote) | 0 (0%) | 22 | All cases (confirmed by fecal elastase) | NA | GI medication, antibiotics, and probiotics held >72 h | Unmatched | MTS-1 Capsule fasting | NA | Held | 7 h max | 3/6 | No difference (CF slower, but |
| Gelfond et al. [ | 20 (10/10) | Sweat Cl > 60 mmol/L or 2 | 0 (0%) | 22.9 | All cases (confirmed by fecal elastase, coefficient of fat absorption or serum trypsinogen) | FEV1 > 25% predicted | Antiacids and antibiotics held >1 week | Age, sex, BMI | Smartpill with low fat meal bar | Solid | Half their usual dose | 72 h max | 5/6 | No difference |
|
| ||||||||||||||
| C-Octanoic breath test | ||||||||||||||
| Symonds et al. [ | 22 (10/12) | Sweat Cl > 80 mmol/L or “genotype determination” | NA | NA | All cases (confirmed by coefficient of fat absorption or steatorrhea + microscopic stool fat) | NA | Not taking any GI motility medication | Unmatched | Pancake, toast, orange juice, and milk | Solid | Usual dose | 8 h | 3/6 | No difference |
|
| ||||||||||||||
| Scintigraphy with technetium | ||||||||||||||
| Carney et al. [ | 16 (5/11) | NA | 0 (0%) | NA | All cases (confirmed by steatorrhea + high 3-day fecal fat) | FEV1 > 50% predicted | NA | Unmatched | Soup and olive oil | Liquid | Held 14 h prior | 2 h | 4/7 | GE of fat is faster in CF |
| Collins et al. [ | 36 (19/17) | NA | 2 (10.5%) | NA | All cases (confirmed by high 3-day fecal fat) | NA | Not taking any GI motility medication >4 days | Age, sex | Pancake | Solid | Usual dose | 2 h | 7/7 | GE is faster in CF |
| Couturier et al. [ | 101 (48/53) | NA | NA | NA | NA | Severe pulmonary disease pre transplant | NA | Unmatched | Egg, bread meal, and water | Solid | NA | 2/3 of stomach emptied | 5/4 | GE is slower in CF ( |
| Kuo et al. [ | 11 (5/6) | NA | 0 (0%) | 20.0 | All cases (NA) | NA | NA | Unmatched | Smashed potatoes | Solid | Crossover | 3 h | 4/6 | GE is faster in CF ( |
| Mendez et al. [ | 88 (10/78) | NA | NA | 20 | NA | Postlung transplant | NA | Both CF and controls had lung transplanta | Egg | Solid | NA | 1.5 h | 4/4 | Both groups had delayed GE, but CF > controls (44% and 29%, resp.) |
| Rovner et al. [ | 28 (16/12) | NA | 0 (0%) | 19.6 | All cases (confirmed by a fecal elastase)b | FEV1 > 50% predicted | NA | Unmatched | Chocolate shake | Liquid | Standard dose (80,000 lipase U) | 6 h | 6/9 | No difference |
a78 controls had end-stage pulmonary disease: 36, COPD; 32, idiopathic pulmonary fibrosis; 7, alpha-1-antitrypsin deficiency; and 3, scleroderma.
bFour subjects with CF had history of distal DIOS and 1 had history of bacterial overgrowth not being treated at the time of study.
GE = gastric emptying.
CF: cystic fibrosis, NOS: Newcastle-Ottawa score, NA: data not available, DM: diabetes mellitus, and DIOS: distal intestinal obstructive syndrome.